Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma

Abstract Although sequence-based studies show that basal-like features lead to worse prognosis and chemotherapy-resistance compared to the classical subtype in advanced pancreatic ductal adenocarcinoma (PDAC), a surrogate biomarker distinguishing between these subtypes in routine diagnostic practice...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Takahiro Shibayama, Akimasa Hayashi, Masao Toki, Keiichiro Kitahama, Yu-Jui Ho, Kenichiro Kato, Takahiro Yamada, Sho Kawamoto, Komei Kambayashi, Kazushige Ochiai, Koichi Gondo, Naohiro Okano, Jerry P. Melchor, Christine A. Iacobuzio-Donahue, Yoshihiro Sakamoto, Tadakazu Hisamatsu, Junji Shibahara
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-07-01
Subjects:	Pancreatic ductal adenocarcinoma Expressional subtypes Surrogate biomarker Immunohistochemistry
Online Access:	https://doi.org/10.1038/s41598-024-65900-w